GENERIC DRUG PROMOTIONS CARRYING EQUIVALENCE CLAIMS ARE NOT REMINDER ADS
Executive Summary
GENERIC DRUG PROMOTIONS CARRYING EQUIVALENCE CLAIMS ARE NOT REMINDER ADS and therefore require full disclosure or a brief summary, FDA's Division of Drug Marketing, Advertising and Communications stated in an April "Current Issues and Procedures" letter. DDMAC mailed 800 copies of the update along with a revised "Pre-approval Promotion Guidance" to all NDA, ANDA and AADA holders on April 22.